Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SWEDISH ORP BIO (BIOVF : OTC)
 
 • Company Description   
Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company's product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden.

Number of Employees: 1,509

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.75 Daily Weekly Monthly
20 Day Moving Average: 986 shares
Shares Outstanding: 299.98 (millions)
Market Capitalization: $5,324.61 (millions)
Beta: 0.71
52 Week High: $26.05
52 Week Low: $15.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.56% -1.64%
12 Week 14.52% 7.26%
Year To Date -9.21% -19.60%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Tomtebodavagen 23 A Solna
-
Stockholm,V7 SE-112 76
SWE
ph: 46-8697-2000
fax: -
paula.treutiger@sobi.com http://www.sobi.com
 
 • General Corporate Information   
Officers
Guido Oelkers - CEO & President
Hakan Bjorklund - Chairman
Henrik Stenqvist - Chief Financial Officer
Annette Clancy - Director
Matthew Gantz - Director

Peer Information
SWEDISH ORP BIO (CORR.)
SWEDISH ORP BIO (RSPI)
SWEDISH ORP BIO (CGXP)
SWEDISH ORP BIO (BGEN)
SWEDISH ORP BIO (GTBP)
SWEDISH ORP BIO (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: W95637117
SIC: -
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 07/15/21
Share - Related Items
Shares Outstanding: 299.98
Most Recent Split Date: (:1)
Beta: 0.71
Market Capitalization: $5,324.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.86 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/15/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 20.64
Trailing 12 Months: 19.29
PEG Ratio: -
Price Ratios
Price/Book: 2.14
Price/Cash Flow: 9.97
Price / Sales: 3.29
EPS Growth
vs. Year Ago Period: -33.33%
vs. Previous Quarter: -34.88%
Sales Growth
vs. Year Ago Period: -9.14%
vs. Previous Quarter: -18.04%
ROE
03/31/21 - 12.50
12/31/20 - 15.28
09/30/20 - 17.14
ROA
03/31/21 - 5.35
12/31/20 - 6.42
09/30/20 - 7.00
Current Ratio
03/31/21 - 0.77
12/31/20 - 0.78
09/30/20 - 0.78
Quick Ratio
03/31/21 - 0.47
12/31/20 - 0.49
09/30/20 - 0.42
Operating Margin
03/31/21 - 16.85
12/31/20 - 18.77
09/30/20 - 20.28
Net Margin
03/31/21 - 19.63
12/31/20 - 21.47
09/30/20 - 19.77
Pre-Tax Margin
03/31/21 - 25.17
12/31/20 - 27.63
09/30/20 - 25.80
Book Value
03/31/21 - 8.29
12/31/20 - 7.34
09/30/20 - 7.06
Inventory Turnover
03/31/21 - 1.09
12/31/20 - 1.37
09/30/20 - 1.64
Debt-to-Equity
03/31/21 - 0.44
12/31/20 - 0.50
09/30/20 - 0.57
Debt-to-Capital
03/31/21 - 30.63
12/31/20 - 33.41
09/30/20 - 36.42
 

Powered by Zacks Investment Research ©